Moderna Inc (NASDAQ:MRNA)
| 80.02 BATS BZX Real-Time Price As of 11:41am ET |  +0.20 / +0.25%Today’s Change | 62.55 Today|||52-Week Range 217.25 | -55.45% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $30.4B |
Company Description
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Contact Information
Moderna, Inc. 200 Technology Square Cambridge Massachusetts 02139 |
Employees
Shareholders
| Mutual fund holders | 38.52% |
| Other institutional | 25.21% |
| Individual stakeholders | 13.67% |
Top Executives
| Stéphane Bancel | Chief Executive Officer & Director |
| Stephen Hoge | President |
| James M. Mock | Chief Financial Officer |
| Paul Burton | Chief Medical Officer |
| Jerh Collins | Chief Technical Operations & Quality Officer |
